SCHEMBL12450834

SCHEMBL12450834

[C-]#[N+]C(C)(C)OCC[C@](C)(N)c1cc([N+](=O)[O-])ccc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR4 O95977 2/20 0.38
ALDH1A1 P00352 5/20 0.38
HIF1A Q16665 1/20 0.38
HTT P42858 2/20 0.37
THRB P10828 2/20 0.37
GAA P10253 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
POLB P06746 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
HSPB1 P04792 3/20 0.34
LMNA P02545 2/20 0.34
CYP3A4 P08684 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
TP53 P04637 1/20 0.34
MAPK1 P28482 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPT P10636 3/20 0.34
KMT2A Q03164 2/20 0.34
NPC1 O15118 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12450823 0.84 ALDH1A1 (0.38) S1PR4ALDH1A1HIF1AHTTTHRB
SCHEMBL18856053 0.83 ALDH1A1 (0.43) S1PR4ALDH1A1HIF1AHTTTHRB
SCHEMBL12272762 0.81 ALDH1A1 (0.38) S1PR4ALDH1A1HIF1AHTTTHRB
SCHEMBL2584469 0.81 ALDH1A1 (0.38) S1PR4ALDH1A1HIF1AHTTTHRB
SCHEMBL2584473 0.81 ALDH1A1 (0.38) S1PR4ALDH1A1HIF1AHTTTHRB
SCHEMBL12077461 0.79 ALDH1A1 (0.45) ALDH1A1HIF1AHTTTHRBGAA
SCHEMBL1977119 0.79 ALDH1A1 (0.45) ALDH1A1HIF1AHTTTHRBGAA
SCHEMBL1977121 0.79 ALDH1A1 (0.45) ALDH1A1HIF1AHTTTHRBGAA
SCHEMBL1981365 0.77 ALDH1A1 (0.51) S1PR4ALDH1A1HIF1AHTTTHRB
SCHEMBL2592336 0.77 ALDH1A1 (0.38) S1PR4ALDH1A1HIF1AHTTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748418-B2 1,4-oxazepines as BACE1 and/or BACE2 inhibitors HOFFMANN-LA ROCHE INC. (US) 2014-06-10 US disclosed
US-8673894-B2 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds HOFFMANN-LA ROCHE INC. (US) 2014-03-18 US disclosed
US-20140045820-A1 2,5,6,7-Tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds HOFFMANN-LA ROCHE INC. (US) 2014-02-13 US disclosed
US-20120238548-A1 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-20 US disclosed
US-20110312937-A1 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS SIENA BIOTECH S.P.A. (IT) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045820-A1 2,5,6,7-Tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds BACE2, BACE1, PSEN2 S1PR4 673/4885ALDH1A1 457/4885HIF1A 2395/4885
US-20110312937-A1 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 S1PR4 673/4885ALDH1A1 457/4885HIF1A 2395/4885
US-20120238548-A1 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS BACE2, BACE1, PSEN2 S1PR4 1982/4885ALDH1A1 485/4885HIF1A 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.